Código QR (código de barras bidimensional)

Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Abstract Improved methods to monitor treatment response may enhance patient management and clinical outcomes. This study assessed the feasibility and performance of a tumor-informed circulating tumor DNA (ctDNA) assay in metastatic HR+/HER2− breast cancer patients receiving endocrine and CDK4/6 inhi...

ver descrição completa

Na minha lista:
Principais autores: Jesús Fuentes-Antrás, Mitchell J. Elliott, Sasha C. Main, Philippe Echelard, Aaron Dou, Philippe L. Bedard, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Emily Van de Laar, Celeste Yu, Yangqing Deng, Lisa Gates, Clodagh Murray, Christopher G. Smith, Amber Chevalier, Scott V. Bratman, Lillian L. Siu, Hal K. Berman, David W. Cescon
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Portfolio 2025-07-01
coleção:npj Breast Cancer
Acesso em linha:https://doi.org/10.1038/s41523-025-00783-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados